Clinical Cardiology Alert – October 1, 2006
October 1, 2006
View Issues
-
ACE Inhibitors for Patients with Normal Left Ventricular Function
Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce mortality and myocardial infarction (MI) in patients with heart failure due to reduced left ventricular (LV) systolic function. -
Bleeding with Acute Coronary Syndrome
In ACS patients without persistent ST-segment elevation, there is a strong, consistent, temporal, and dose-related association between bleeding and death. -
Atrial Fibrillation
The 2006 guidelines for the management of patients with atrial fibrillation clarify previous recommendations for anticoagulation to prevent other thromboembolic events. -
Embolic Risk Post Ablation
Discontinuation of anticoagulation 3-6 months after successful atrial fibrillation ablation is reasonable in low-risk patients. -
Another New Biomarker for Cardiovascular Disease
Among elderly persons without chronic kidney disease, cystatin C is a prognostic biomarker of risk for death, cardiovascular disease, and chronic kidney disease. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
A team from UCSF recently reviewed company documents that were entered into the public record as a result of litigation over the promotion of gabapentin (Neurontin) between 1994 and 1998. -
Ace Inhibitors for Abdominal Aortic Aneurysms
ACE inhibitors are associated with a reduced risk of ruptured abdominal aortic aneurysm, unlike other antihypertensive agents. Randomised trials of ACE inhibitors for prevention of aortic rupture might be warranted.